<unk>  is indicated for the treatment of adults with locally advanced (when cancer has grown too large to be surgically removed) or metastatic (when cancer cells spread to other parts of the body) urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.
Enfortumab vedotin
Sacituzumab govitecan
Tisotumab vedotin
Loncastuximab tesirine
Polatuzumab vedotin
Acalabrutinib
Lanadelumab
Selpercatinib